Company / Revenue
Outlook Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.4M
FY2025
5-year range
$1.4M / $8.1M
FY2021-FY2025
Trend
-82.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 6 years, ranging from $1M in FY2025 to $8M in FY2020.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -29.6%.
Declined from $3M to $1M over the past 6 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -29.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -29.6%, indicating a declining trend.
- In FY2025, revenue decreased 82.6% year-over-year.
- Peak revenue was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | -82.6% |
| FY2020 | $8.1M | +163.8% |
| FY2019 | $3.1M | -19.0% |
| FY2018 | $3.8M | +27.9% |
| FY2017 | $3.0M | -42.9% |
| FY2016 | $5.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026